Every 8-K that Intuitive Surgical Inc. (ISRG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ISRG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ISRG filings page.
Intuitive Surgical, Inc. amended and restated its bylaws on July 23, 2026. The changes allow the company to disregard votes for director nominees submitted by shareholders who do not comply with SEC universal proxy rules, including soliciting holders of 67% of outstanding shares.
The bylaws add expanded disclosure requirements for shareholder director nominations and other business proposals, covering synthetic equity (using SEC-defined terms), investment dates and intent, and proposed bylaw amendment language. Procedural changes limit nominees to the number of seats up for election, require requesting shareholders to be record holders, and require the shareholder to be present in person at meetings.
Additional revisions require any shareholder soliciting proxies to use a non-white proxy card, establish logistics and disclosures for requesting a record date to determine who can call a special meeting, change the voting standard for corporate actions (other than elections) to a majority of votes cast excluding abstentions and broker non-votes, and make conforming technical updates.
Intuitive Surgical reported second-quarter 2026 results showing broad-based growth. Revenue rose 19% to $2.89 billion, driven by approximately 16% worldwide procedure growth for da Vinci and Ion systems (da Vinci about 15%, Ion about 36%). GAAP net income attributable to Intuitive was $818 million, or $2.29 per diluted share, while non-GAAP net income reached $1.00 billion, or $2.80 per diluted share. The da Vinci installed base increased 12% year over year to 11,710 systems and the Ion installed base 21% to 1,096 systems.
Income from operations increased on both GAAP and non-GAAP bases, and results included a $28 million net benefit, or $0.08 per diluted share, from IEEPA tariff refunds. Intuitive ended the quarter with $8.63 billion in cash, cash equivalents, and investments after repurchasing 0.9 million shares for $0.38 billion. For full-year 2026, the company expects worldwide da Vinci procedure growth of approximately 13.5%–15.5%, non-GAAP gross profit margin of 68.0%–69.0% of revenue (including about a 1% tariff impact), and non-GAAP operating expense growth of 11%–13%, while noting that additional tariffs could materially affect results.
Intuitive Surgical, Inc. has announced an internal leadership change in its commercial organization. Taylor Patton, currently Global Senior Vice President of the company’s endoluminal business, will become Chief Commercial and Marketing Officer effective July 1, 2026 and join the Executive Leadership team.
Current Chief Commercial and Marketing Officer Henry L. Charlton will transition to Senior Vice President of Global Business Operations on the same date. The company highlights Patton’s nearly two decades of experience across its da Vinci, Ion and Digital platforms and notes that Charlton will work closely with Patton to support a smooth transition in global commercial and customer-support activities.
Intuitive Surgical, Inc. increased the authorized amount under its common stock repurchase program to an aggregate $5.0 billion, to be funded with cash, cash equivalents, and investments. Repurchases may occur over time through open-market and other transactions and may be suspended or discontinued at any time.
At its April 30, 2026 annual meeting, stockholders elected ten directors, approved on an advisory basis the compensation of named executive officers, ratified PricewaterhouseCoopers LLP as auditor for the year ending December 31, 2026, and approved an amendment and restatement of the 2010 Incentive Award Plan.
The amended plan increases shares reserved for awards from 120,350,000 to 125,350,000, extends the plan term to January 29, 2036, and further specifies how awards are treated in a change in control.
Intuitive Surgical reported strong first quarter 2026 results, driven by double-digit growth in robotic procedures and system placements. Revenue reached $2.77 billion, up 23% from $2.25 billion a year earlier, as worldwide procedures for da Vinci and Ion systems grew about 17%.
Instruments and accessories revenue rose to $1.69 billion, up 23%, while systems revenue increased to $651 million from $523 million, supported by 431 da Vinci system placements, including 232 da Vinci 5 systems. The installed base expanded to 11,395 da Vinci and 1,041 Ion systems as of March 31, 2026.
GAAP net income attributable to Intuitive Surgical, Inc. was $822 million, or $2.28 per diluted share, compared with $698 million, or $1.92, a year earlier. Non-GAAP net income was $901 million, or $2.50 per diluted share. The company ended the quarter with $7.98 billion in cash and investments and repurchased 2.3 million shares for $1.1 billion. For full-year 2026, Intuitive expects worldwide da Vinci procedure growth of 13.5%–15.5%, non-GAAP gross margin of 67.5%–68.5%, and non-GAAP operating expense growth of 11%–14%.
Intuitive Surgical, Inc. has completed its acquisition of the da Vinci and Ion distribution business operated by ab medica, Abex, Excelencia Robótica, and their affiliates. This move shifts Intuitive to direct commercial operations in Italy, Spain, Portugal, Malta, San Marino, and associated territories.
The acquired business is now wholly owned and integrated into Intuitive’s European commercial and marketing organization, led by Senior Vice President and General Manager Dirk Barten. Approximately 250 employees are joining Intuitive as part of this expansion.
There were more than 470 da Vinci surgical systems installed in Italy, Spain, and Portugal as of December 31, 2025, providing an established base for Intuitive’s expanded direct presence in minimally invasive and robotic-assisted surgery in Southern Europe.
Intuitive Surgical, Inc. filed a current report stating that it issued a press release announcing its financial results for the quarter ended December 31, 2025. The press release is furnished as Exhibit 99.1, giving investors access to the company’s quarterly performance details outside this report.
The company notes that the information contained in the report, including Exhibit 99.1, is being furnished rather than filed, meaning it is not subject to certain liability provisions under the Securities Exchange Act and is not automatically incorporated into other SEC filings. The report is signed on behalf of Intuitive by its Executive Vice President and Chief Financial Officer, Jamie E. Samath.
Intuitive Surgical, Inc. furnished a report stating that it has issued a press release with unaudited preliminary financial results for the fourth quarter and full year 2025. The release is provided as Exhibit 99.1.
The company also supplied additional unaudited preliminary revenue and procedure information in tabular form as Exhibit 99.2, which has been posted to the Investor Relations section of its website. The materials are designated as furnished rather than filed, meaning they are not subject to certain Exchange Act liabilities or automatically incorporated into other securities law filings.
Intuitive Surgical, Inc. reported a leadership role change in its digital organization. Effective January 1, 2026, Brian E. Miller, Ph.D., will move from his current position as Chief Digital Officer to become Head of Digital and AI Strategy. In this new role, Dr. Miller will continue focusing on the company’s digital and artificial intelligence initiatives but will no longer report directly to the Chief Executive Officer. The filing does not describe additional changes to his responsibilities or to other executive roles.
Intuitive Surgical (ISRG) furnished an 8-K announcing quarterly results. On October 21, 2025, the company issued a press release with financial results for the quarter ended September 30, 2025, attached as Exhibit 99.1. The materials are furnished and not deemed filed under the Exchange Act.